<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824731</url>
  </required_header>
  <id_info>
    <org_study_id>STR - ProtoChoice-Hirn - 2015</org_study_id>
    <nct_id>NCT02824731</nct_id>
  </id_info>
  <brief_title>Comparison of Proton and Photon Radiotherapy of Brain Tumors (ProtoChoice-Hirn)</brief_title>
  <official_title>Comparison of Proton and Photon Radiotherapy of Brain Tumors: Efficiency and Side Effects in Clinical Standard Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Consortium (DKTK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Radiation Research in Oncology Dresden/Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol compares the toxicity of radiotherapy or radiochemotherapy applied with
      different radiation modalities - protons or photons. Patients with different kinds of brain
      tumours and foreseen high-dose radiotherapy can be included. The hypothesis of the trial is
      that the rate of chronic toxicity 1 year after the end of radiotherapy is 15% lower after
      proton compared to photon treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-randomised 2-arm phase II trial on comparison of proton versus photon radiotherapy in
      brain tumours using standard doses and standard combined chemotherapy protocols. Patients are
      assigned to the treatment groups by their own choice or availability of the treatment.
      Patients are stratified into 4 groups, (1) supratentorial grad III/ IV tumours without
      pre-irradiation; (2) supratentorial grade I/II tumours without pre-irradiation; (3)
      infratentorial tumours without pre-irradiation; (4) patients with pre-irradiation &gt;40 Gy in
      the tumour area. Radiotherapy doses of 54-60 Gy(RBE) are applied in group 1-3 using normal
      fractionated schedules. In group 4, 30 Gy(RBE)/ 5 Gy(RBE) per fraction or 36 Gy(RBE) with 2
      Gy(RBE) per fraction are allowed. Primary endpoint is chronic toxicity and quality of life.
      The hypothesis of the trial is that the rate of chronic toxicity 1 year after the end of
      radiotherapy is 15% lower after proton compared to photon treatment. Events for chronic
      toxicity are toxicities observed later than 3 months after end of radiotherapy and scored
      CTC-AE4.0 &gt;grade 2 or a decrease in Quality of life by &gt;10% (EORTC-QLQ C30 and BN20) or a
      decrease in neuropsychological functioning by &gt;10% (MoCa test). All statistical calculations
      apply to group (1), i.e. supratentorial grade II/IV tumours without pre-irradiation, all
      other arms are closed when group (1) is closed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>late toxicity as cumulative measure</measure>
    <time_frame>1 year after end of treatment</time_frame>
    <description>Events for the endpoint are:
any late toxicity CTCAE 4.0 ≥ grade II (except pre-existing conditions)
decrease in Quality of life (EORTC-QLQ-C30 and BN20) by &gt;10%
decrease in brain function (MOCA test) by more than 10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local tumour control</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Local tumour control as Regression or stable disease measured in follow-up MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>acute toxicity according to CTCAE4.0 score &gt;/= grade II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity as cumulative measure</measure>
    <time_frame>2 years</time_frame>
    <description>Events for the endpoint are:
any late toxicity CTCAE 4.0 ≥ grade II (except pre-existing conditions)
decrease in Quality of life (EORTC-QLQ-C30 and BN20) by &gt;10%
decrease in brain function (MOCA test) by more than 10%</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">346</enrollment>
  <condition>Brain Tumors</condition>
  <arm_group>
    <arm_group_label>supratentorial, grade III/IV, photon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>supratentorial, grade III/IV, proton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>supratentorial, grade I/II, photon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients, bening tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>supratentorial, grade I/II, proton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients, bening tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>infratentorial, photon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>infratentorial, proton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pre-radiation, photon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&gt; 40Gy in the region of recurrence. Radiation with photons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pre-radiation, proton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&gt; 40Gy in the region of recurrence. Radiation with protons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation with protons</intervention_name>
    <arm_group_label>supratentorial, grade III/IV, proton</arm_group_label>
    <arm_group_label>supratentorial, grade I/II, proton</arm_group_label>
    <arm_group_label>infratentorial, proton</arm_group_label>
    <arm_group_label>pre-radiation, proton</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation with photons</intervention_name>
    <arm_group_label>supratentorial, grade III/IV, photon</arm_group_label>
    <arm_group_label>supratentorial, grade I/II, photon</arm_group_label>
    <arm_group_label>infratentorial, photon</arm_group_label>
    <arm_group_label>pre-radiation, photon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary brain tumor: gliomas (low or high grade), intracerebral meningiomas, pituitary
             adenomas, craniopharyngioma and other rare brain tumors

          -  brain tumor recurrence without pre-irradiation

          -  brain tumor recurrence with pre-irradiation &gt; 40 Gy in the overlap region with the
             recurrence region

          -  indication for radiotherapy or radiochemotherapy

          -  Both proton and photon therapy are possible from a medical point of view (that is no
             standard indication for protons or standard indication for example one-time stereotaxy

          -  age &gt;= 18 years

          -  general condition ECOG ≤ 2, outpatient basis possible

          -  indication for high dose (except group 4) radiotherapy or radiochemotherapy

          -  capacity to consent and present written informed consent

        Exclusion Criteria:

          -  lack of capacity to consent or lack of written consent

          -  cerebral lymphomas

          -  brain metastases

          -  very small tumors (for example acoustic neuromas, very small recurrences) for this is
             a proton therapy from a medical point of view no alternative to a stereotactic
             radiotherapy

          -  inability to MRI planning (eg. contraindications to performing MRI)

          -  lack of compliance of the patient

          -  lack of or limited possibility of a reproducible storage (eg by severe restriction of
             mobility of the patient)

          -  missing or limited possibility of regular follow-up visits in accordance with the
             study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mechthild Krause, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mechthild Krause, Prof.</last_name>
    <phone>+49 351 458 5441</phone>
    <email>mechthild.krause@uniklinikum-dresden.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus, Department of Radiotherapy and Radiation Oncology</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mechthild Krause, Prof.</last_name>
      <phone>+49 351 458 5441</phone>
      <email>mechthild.krause@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Mechthild Krause</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>brain tumors</keyword>
  <keyword>proton radiotherapy</keyword>
  <keyword>photon radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

